Acessibilidade / Reportar erro
REVISÃO TEMÁTICA • Arq. Bras. Oftalmol. 61 (4) • Aug 1998 • https://doi.org/10.5935/0004-2749.19980046   copiar

Atualização no tratamento das afecções oculares por herpes simples vírus

Update on the treatment of herpetic eye disease

Autoria SCIMAGO INSTITUTIONS RANKINGS

Texto completo disponível apenas em PDF.

  • O autor não tem interesse comercial ou proprietário sobre os produtos e fármacos citados.

REFERÊNCIAS BIBLIOGRÁFICAS

  • 1
    US Departament of Health and Human Services. External ocular infections and inflamatory disease. ln: Vision research: a national plan 1983-1987 (NIH publication n 83-2472), Washington, DC, National Eye Institute, 1983.
  • 2
    Liesegang TJ. A community study of ocular herpes simplex. Curr Eye Res 1991; 10(Suppl):111-5.
  • 3
    Remeijer L, Doornembal P, Gerards DJM et al. Newly acquired herpes simplex virus keratitis after penetrating keratoplasty. Ophthalmol 1997;104:648-52.
  • 4
    Lee SY, Laibson PR. Medical management of herpes simplex ocular infections. Int Ophthalmol Clin 1996;36:85-97.
  • 5
    Sterk CC, Jager MJJ, Berg MS. Recurrent herpetic keratitis in penetrating keratoplasty. Documenta Ophthalmol 1995;90:29-33.
  • 6
    Cockerham GC, Krafft AE, McLean IW. Herpes simplex virus in primary graft failure. Arch Ophthalmol 1997; 115:586-9.
  • 7
    Kaufman HE, Martola EL, Dohlman C. Use of 5-iodo-2-deoxyuridine (IDU) in the treatment ofherpes simplex keratitis. Arch Ophthalmol 1962;68:223-38.
  • 8
    Colin J. Superficial herpes simplex keratitis - a double-blind comparative triai of acyclovir and idoxiuridine. Nouv Press Med 1981; 10:2969-75.
  • 9
    La Lau C, Oosterhuis J, Versteeg J et al. Acyclovir and trifluorothymidine in herpetic keratitis. A multicenter trial. Br J Ophthalmol 1982;66:506-8.
  • 10
    Collum LMS, Logan P, McAulife-Curtin D et al. Randomised double-blind trial of acyclovir and adenina arabinoside in herpes simplex amoeboid corneal ulceration. Br J Ophthalmol 1985;69:847-50.
  • 11
    Erlich KS, Mills J, Chatis P et al. Acyclovir resistant herpes simplex virus infection in patients with AIDS. N Eng J Med 1989;320:293-6.
  • 12
    Sonkin PL, Baratz KH, Frothinghan R et al. Acyclovir resistant herpes simplex keratouveitis after penetraing keratoplasty. Ophthalmology 1992;99: 1805-8.
  • 13
    Markham A, Falch D. Gancyclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994;48:455-84.
  • 14
    Shiota H, Naito T, Mimura Y. Antiherpes simplex virus effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine in rabbit cornea. Curr Eye Res 1987;6:241-5.
  • 15
    Trousdale MD, Nesburn AB, Willey DE et al. Efficacy of BW759 9-(1,3-dihydroxi-2-propoxymethyl) guanine against herpes simplex virus type 1 keratitis in rabbits. Curr Eye Res 1984;3:1007-15.
  • 16
    Hoh HB, Harley C, Claone C at al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: A multicenter study. Br J Ophthalmol 1996;80:140-3.
  • 17
    Colin J, Hoh HB, Easty DL et al. Gancyclovir ophthalmic gel (Virgan 0,15%) in the treatment of herpes simplex keratitis. Cornea 1997;16(4):393-9.
  • 18
    Spector SA, Weigenst T, Pollard RB et al. A randomised controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-63.
  • 19
    Maudgal PC, Missotten L, De Clercq E et al. (E)-5-(2-bromovinyl)-2-deoxyuridine in the topical treatment of herpes simplex keratitis. Graeffes Arch Clin Exp Ophthalmol 1981;216:261-8.
  • 20
    Maudgal PC, Dieltiens M, De Clercq E et al. Topical bromovinyldeoxiuridine treatment ofherpes simplex keratitis. Doc Ophthalmol Proc Ser 1985;44:247-56.
  • 21
    Panda A, Das GK, Khokhar S, Rao V. Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. Can J Ophthalmol 1995;30:256-8.
  • 22
    Weller S, Blun MR, Donnetti T et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharm Ther 1993;54:595-605.
  • 23
    Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infection. Drugs 1996;52:754-72.
  • 24
    Pue HD, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993;4:47-55.
  • 25
    Luber AD, Flaherty JF Jr. Famciclovir for treatment ofherpesvirus infections. Ann Pharrnacother 1996;30:978-85.
  • 26
    Cumpacker C. The pharmacological profile of famciclovir. Semin Dermatol 1996;15:14-26.
  • 27
    Isaacs A, Lindenmann J. Virus interference. 1. The interferon. Proc R Soc Lond B 1957;147:258-67.
  • 28
    Sundmacher R, Cantell K, Hang P, Newmann-Haefelin D. Interpheron-Prophylaxe von Dendritica-Rezidiven bei lokale Steroidtherapie. Ber Dtsch Ophthalmol Ger 1977;75:344-6.
  • 29
    Sundmacher R, Cantell K, Hang P, Newmann-Haefelin D. Role of debridement and interferorn in the treatment of dendritic keratitis. Albrech v Graefes Arch Klin Exp Ophthalmol 1978;207:77-82.
  • 30
    Coster DJ, Falcon MG, Cantell K, Jones BR. Clinical experience of human leukocyte interferon in the management of herpetic keratitis. Trans Ophthalmol Soc UK 1977;97:327-9.
  • 31
    Sundmacher R, Cantell K, Newmann-Haefeli D. Combination therapy of dendritic keratitis with trifluorothymidine and interferon. Lancet 1978;ii:687.
  • 32
    Colin J, Chastel C, Renard G, Cantell K. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir. Am J Ophthalmol 1983;95:346-8.
  • 33
    De Konieg EWJ, van Bijsterveld OP, Cantell K. Combination therapy for dendritic keratitis with acyclovir and alpha-interferon. Arch Ophthalmol 1983;101:1866-8.
  • 34
    Minkovitz JB, Pepose JS. Topical interferon alpha-2 treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosupressed patient. Cornea 1995;14:326-30.
  • 35
    Santoro MG, Benedetto G, Carruba E et al. Prostaglandin A compounds as antiviral agents. Science 1980;209: 1032-4.
  • 36
    O'Brien WJ, Taylor JL, Ankel H, Sitenga G. Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis. Antimicrob Agents Chemother 1996;40:2327-31.
  • 37
    Shiota H, Nitta K, Naito T et al. Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers. Br J Ophthalmol 1996:80:413-5.
  • 38
    Shiota H, Nitta K, Naito T et al. Effect of carbocyclic oxetanocin on herpetic keratitis. Chemother 1992;40:841-2.
  • 39
    Klenk HD, Garten W. Host cell proteases controlling virus pathogenicity. Trends Microbiol 1994;2:39-43.
  • 40
    Aoki H, Akaike T, Abe K et al. Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type 1 in vitro and in vivo. Antimicrob Agents Chemother 1995;39:846-9.
  • 41
    Brandt CR, Spencer B, Imesch P et al. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model oh herpes simplex virus type 1 ocular disease. Antimicrobiol Agents Chemother 1996;40:1078-84.
  • 42
    Kaufman HE, Varnell ED, Wright GE et al. Effect of 9-(4-hidroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, on clinicai recurrences of ocular herpetic keratitis in squirrel monkeys. Antivirai Res 1996;33:65-72.
  • 43
    Gebbhardt BM, Wright GE, Xu H et al. 9-(4-hidroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, suppresses herpes virus reactivation in mice. Antiviral Res 1996;30:87-94.
  • 44
    Gebbhardt BM, Kaufman HE. Propanolol supresses reactivation of herpesvirus. Antiviral Res 1995;27(3):255-61.
  • 45
    Meduri R, Campos E, Scorolli L et ai. Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 1996;9:61-6.
  • 46
    Estrada-Parra S, Chávez-Sánchez R, Ondarza-Aguillera R et al. Immunotherapy with transfer factor of recurrent herpes simplex type 1. Arch Med Res 1995;26:s87-92.
  • 47
    De Maria A, Tundo P, Romao A, Grima P. Anti-HSV-1 herpes vaccination by Lupidon H: Preliminary results. In Advances in mucosal immunology, ed. by J. Mestecky et ai, Plennum Press, New York 1995; 1599-600.
  • 48
    Staats HF, Oakes JE, Lausch RN. Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets of asialo GM 1 + cells. J Virol 1991;65:6008.
  • 49
    Inoue Y, Oh JO, Minasi P. Protective effect of anti-glycoprotein D antibody on herpetic chorioretinitis in newborn rabbits. Curr Eye Res 1991;10:159.
  • 50
    Gamus D, Romano A, Rubinstein M, Savion N. Moderation ofherpetic stromal keratitis by basic fibroblast growth factor. Exp Eye Res 1996;63: 1-8.

Datas de Publicação

  • Publicação nesta coleção
    Aug 1998
Creative Common - by 4.0
Este é um artigo publicado em acesso aberto (Open Access) sob a licença Creative Commons Attribution, que permite uso, distribuição e reprodução em qualquer meio, sem restrições desde que o trabalho original seja corretamente citado.
Conselho Brasileiro de Oftalmologia Rua Casa do Ator, 1117 - cj.21, 04546-004 São Paulo SP Brazil, Tel: 55 11 - 3266-4000, Fax: 55 11- 3171-0953 - São Paulo - SP - Brazil
E-mail: abo@cbo.com.br
Acompanhe os números deste periódico no seu leitor de RSS